According to government estimates, the opioid epidemic has reached crisis proportions, and now costs the US more than $500 billion annually. Of this total, $432 billion is from the total cost of fatalities and $72 billion is from non-fatality costs
As our nation works tirelessly to address the coronavirus (COVID-19), on behalf of the pharmacy benefit management (PBM) industry, the Pharmaceutical Care Management Association (PCMA) affirms our commitment to support federal, state, and local public health agencies; collaborate with health
Ohio Medicaid takes better advantage of the expansive industry relationships and pharmacy networks that PBMs have built to provide patients with ready access to pharmaceuticals
Dr. Lawton Robert Burns, a professor at the University of Pennsylvania Wharton School and an expert on the medical and prescription drug supply chains, took a deep dive into pharmacy benefit companies and shed light on the role of PBMs.
The Pharmaceutical Care Management Association (PCMA), the national trade association representing America’s pharmacy benefit managers, has named JC Scott the association’s next President and CEO, effective October 15. Scott is currently the Chief Advocacy Officer for the Advanced Medical Technology
A new book from the University of Pennsylvania Wharton School professor Lawton Robert Burns examines pharmacy benefit companies and describes their critical role in the prescription drug supply chain. Burns concludes that PBMs are intermediaries using tools to control healthcare
(Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) President and CEO Mark Merritt released the following statement on the House Energy and Commerce Health Subcommittee’s hearing Combating the Opioid Crisis: Improving the Ability of Medicare and Medicaid to Provide Care
(Washington, D.C.) — Pharmaceutical Care Management Association President and CEO Mark Merritt issued the following statement on the Administration’s announcement to provide Medicare Part D plans additional flexibility in designing Medicare Part D formularies around medical indications. “While PCMA is
(Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott issued the following statement on the Senate’s passage of the Bipartisan Infrastructure Framework legislation: “We are encouraged that there is bipartisan support for repealing the Medicare rebate
If drug companies had their way there would be no check on their power. But they don’t. Pharmacy benefit companies exist to control costs.
©2024 PCMA. All Rights Reserved.
